Survival in patients with synchronous liver metastases in central and northern Denmark, 1998 to 2009

Original Research

(3891) Total Article Views

Authors: Høyer M, Erichsen R, Gandrup P, Nørgaard M, Jacobsen JB

Published Date July 2011 Volume 2011:3(Supplement 1) Pages 11 - 17

DOI: http://dx.doi.org/10.2147/CLEP.S20613

Morten Høyer^1,2, Rune Erichsen¹, Per Gandrup³, Mette Nørgaard¹, Jacob Bonde Jacobsen^1
1Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark; ²Department of Oncology, Aarhus University Hospital, Aarhus, Denmark; ³Department of Gastrointestinal Surgery, Aarhus University Hospital, Aalborg, Denmark

Objective: In Denmark, the strategy for treatment of cancer with metastases to the liver has changed dramatically during the period 1998 to 2009, when multidisciplinary care and a number of new treatments were introduced. We therefore examined the changes in survival in Danish patients with colorectal carcinoma (CRC) or other solid tumors (non-CRC) who had liver metastases at time of diagnosis.
Study design and methods: We included patients diagnosed with liver metastases synchronous with a primary cancer (ie, a solid cancer diagnosed at the same date or within 60 days after liver metastasis diagnosis) during the period 1998 to 2009 identified through the Danish National Registry of Patients. We followed those who survived for more than 60 days in a survival analysis (n = 1021). Survival and mortality rate ratio (MRR) at 1, 3, and 5 years stratified by year of diagnosis were estimated using Cox proportional hazards regression analysis.
Results: In the total study population of 1021 patients, 541 patients had a primary CRC and 480 patients non-CRC. Overall, the 5-year survival improved from 3% (95% confidence interval [CI]: 1%–6%) in 1998–2000 to 10% (95% CI: 6%–14%) in 2007 to 2009 (predicted value). The 5-year survival for CRC-patients improved from 1% (95% CI: 0%–5%) to 11% (95% CI: 6%–18%) whereas survival for non-CRC patients only increased from 5% (95% CI: 1%–10%) to 8% (95% CI: 4%–14%).
Conclusion: We observed improved survival in patients with liver metastases in a time period characterized by introduction of a structured multidisciplinary care and improved treatment options. The survival gain was most prominent for CRC-patients.

Keywords: liver metastases, colorectal cancer, noncolorectal cancer, survival improvement

Readers of this article also read: